Pegcetacoplan

What it's for

Pegcetacoplan is a PEGylated peptide that targets complement C3. Empaveli treats paroxysmal nocturnal hemoglobinuria; Syfovre is an intravitreal product for geographic atrophy secondary to AMD — same peptide chemistry, different products/labels.

What it does for the body

Empaveli treats paroxysmal nocturnal hemoglobinuria; Syfovre is an intravitreal product for geographic atrophy secondary to AMD — same peptide chemistry, different products/labels.

What it targets

C3 inhibition blocks proximal complement activation, reducing intravascular hemolysis (PNH) or complement-driven retinal degeneration pathways (GA). Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.

Research context

Bottom line for readers: Pegcetacoplan has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.

Studied for (literature interest)

• Heart research interest (educational tag)

Cautions (educational)

• Educational only — not medical advice.
• DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.

Citations / starters

• FDA search: Pegcetacoplan — FDA.gov search
• ClinicalTrials.gov search: Pegcetacoplan — U.S. clinical trials registry
• Drugs@FDA search: Pegcetacoplan — FDA drug database (if approved)
• PubMed search: Pegcetacoplan — NCBI PubMed
• PubMed Central search: Pegcetacoplan — NCBI PMC

Reference

No ref on file.